The media goes wild. This time around, the media is making a fuss about Vertex Pharmaceuticals Incorporated’s suzetrigine, a newly FDA-approved painkiller that also goes by the equally ...

The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than ...

Vertex Pharma's non-opioid painkiller suzetrigine was unable to perform better than placebo in a phase 2 trial in lumbosacral radiculopathy (LSR), a form of neuropathic back pain, ahead of an FDA ...

The media goes wild. This time around, the media is making a fuss about Vertex Pharmaceuticals Incorporated’s suzetrigine, a newly FDA-approved painkiller that also goes by the equally unpronounceable ...

The drug is suzetrigine under the brand name Journavx. It is now FDA-approved to treat moderate to severe acute pain, which is usually caused by injury, trauma or surgery. Pain is registered in ...

The Food and Drug Administration (FDA) recently approved a new, non-opioid (non-narcotic) prescription pill, suzetrigine (SUE ...

Journavx (suzetrigine) is a new nonopioid medication manufactured by Vertex Pharmaceuticals to help treat and manage moderate to severe acute pain. While opioids work by attaching to special ...

Vertex Pharma has secured FDA approval for its non-opioid pain drug suzetrigine, becoming the first new class of pain medicine in the US in more than 20 years. The oral NaV1.8 inhibitor has been ...

The FDA's nod for suzetrigine bolsters confidence in the pharmaceutical industry's strategy to target sodium channels. Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) has recently achieved a significant ...

All eyes are on Jan. 30, when the FDA weighs in on suzetrigine -- a potential game-changer for pain treatment that could offer an alternative to addictive opioids. If approved, Wall Street ...

The drug, suzetrigine, is a 50-milligram prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx. “A new non-opioid analgesic ...